Non-steroidal anti-inflammatory drugs for acute gout

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  van Durme, Caroline M P G ^a,b   Wechalekar, Mihir D ^c   Buchbinder, Rachelle ^d   Schlesinger, Naomi ^e   van der Heijde, Désirée ^f   Landewé, Robert B M ^g,h  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c REPATRIATION GENERAL HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h Sittard Geleen Heerlen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; ETODOLAC; GLUCOCORTICOID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TENOXICAM; CYCLOOXYGENASE 2 INHIBITOR;

ACUPUNCTURE; DRUG EFFICACY; DRUG SAFETY; GOUT; HUMAN; INFLAMMATION; INFRARED RADIATION; JOINT SWELLING; META ANALYSIS; NUMERIC RATING SCALE; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SIDE EFFECT; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; WALKING DIFFICULTY; ACUTE DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; GOUT; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84906881730     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010120.pub2     Document Type: Review

References (74)

1. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. Journal of Rheumatology 1988;15:1422-6.
2. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis & Rheumatism 1988;31:803-5.
3. Butler RC, Goddard DH, Higgens CS, Hollingworth P, Pease CT, Stodell MA, et al.Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. British Journal of Clinical Pharmacology 1985;20:511-3.
4. Cheng T-T, Lai H-M, Chiu C-K, Chem Y-C. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clinical Therapeutics 2004;26:399-406.
5. Douglas G, Thompson M. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. Annals of Physical Medicine 1970;10:275-80.
6. Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittel-Forschung 1983;33(4A):641-3.
7. Garcia de la Torre I. A comparative, double-blind, parallel study with tenoxicam vs placebo in acute gouty arthritis [Estudio doble-ciego paralelo, comparativo con tenoxicam vs placebo en artritis gotosa aguda]. Investigación Médica Internacional 1987;14:92-7.
8. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60.
9. Klumb EM, Pinheiro GRC, Ferrari A, Albuquerque EMN. The treatment of acute gout arthritis. Double-blind randomized comparative study between nimesulid and indomethacin [O tratamento da crise aguda de gota. Estudo duplo-cego, randômico, comparativo entre o nimesulide e a indometacina]. Revista Brasileira de Medicina 1996;53(6):540-46.
10. Lederman R. A double-blind comparison of etodolac (Lodine) and high doses of naproxen in the treatment of acute gout. Advances in Therapy 1990;7(6):344-54.
11. Lomen PL, Turner LF, Lamborn KR, Winbald MA, Sack RL, Brinn EL. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. American Journal of Medicine 1986;80(3A):134-9.
12. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Current Medical Research and Opinion 1991;12:423-9.
13. Man CY, Cheung ITF, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Annals of Emergency Medicine 2007;49:670-7.
14. Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, Pryhuber KG, et al.Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis & Rheumatism 2004;50:598-606.
15. Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al.Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.
16. Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F, Burgos-Vargas R, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. Journal of Rheumatology 2012;39:1859-66.
17. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Annals of Emergency Medicine 1995;26:682-6.
18. Siegmeth W, Placheta P. Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis (author's translation). Wiener Klinische Wochenschrift 1976;88:535-7.
19. Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Annals of the Rheumatic Diseases 1973;32:351-3.
20. Sturge RA, Scott JT, Hamilton EB, Liyanage SP, Dixon AS, Davies J, et al.Multicentre trial of naproxen and phenylbutazone in acute gout. Annals of the Rheumatic Diseases 1977;36:80-2.
21. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HSB, Evans RR, Wang J, et al.Rilonacept in the treatment of acute gouty arthritis: a randomised, controlled clinical trial using indomethacin as the active comparator. Arthritis Research & Therapy 2013;15:R25.
22. Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, et al.Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology 2007;46(7):1126-32.
23. Zhou L, Xu QF, Zhang WS. Comparative observation of therapeutic effects of acupuncture combined with infrared irradiation and western medicine on acute gouty arthritis. World Journal of Acupuncture 2012;22(1):30-4.
24. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. Journal of Rheumatology 1993;20:111-3.
25. Arnold MH, Preston SJ, Buchanan WW. Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal-anti-inflammatory drugs. British Journal of Clinical Pharmacology 1988;26:488-9.
26. Bach GL. The acute gout attack [Der akute gichtaanfall]. Medizinische Welt 1979;30(45):1696-8.
27. Cunovic S. Treatment of acute uric arthritis using perclusone [Lijecenje akutnog napadaja urickog artritisa Perclusone-om]. Reumatizam 1973;20(4):156-9.
28. Cuq P. Treatment of acute attacks of gout with naproxen-C 1674. Scandinavian Journal of Rheumatology Supplement 1973;2:64-8.
29. Kudaeva FM, Eliseev MS, Barskova VG, Nasonova VA. Comparison of the time to analgetic and anti-inflammatory effect in the treatment of gouty arthritis with nimesulide and sodium diclofenac. Terapevticheskii Arkhiv 2007;79(5):35-40.
30. Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM. Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout. Current Medical Research and Opinion 2007;23:1685-91.
31. Wortmann R. Apremilast therapy for acute gouty arthritis. ClinicalTrials.gov.
32. Reardon JA, Stockman A, Darlington LG, Scott JT. Double-blind trial of feprazone and phenylbutazone in acute gout. Current Medical Research and Opinion 1980;6:445-8.
33. Ruotsi A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. Scandinavian Journal of Rheumatology Supplement 1978;21:15-7.
34. Tumrasvin T, Deesomchok U. Piroxicam in treatment of acute gout high dose versus low dose. Journal of the Medical Association of Thailand 1985;68(3):111-16.
35. Valdes EF. Use of tenoxicam in patients with acute gouty arthritis. European Journal of Rheumatology & Inflammation 1987;9(2):133-6.
36. Weiner GI, White SR, Weitzner RI, Rubinstein HM. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis & Rheumatism 1979;22:425-6.
37. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. Revue du Rhumatisme (English ed.) 1996;63:248-54.
38. Katona G, Burgos-Vargas R. Clinical experiences with the intramuscular injection of tiaprofenic acid in rheumatic diseases, with particular emphasis on time of onset and duration of the analgesic effect. Drugs 1988;35 Suppl 1:72-80.
39. Monov S, Monova D. Oxaprozin in patients with gout. Clinical and Experimental Rheumatology 2009;27(5):739.
40. American College of Rheumatology. 1977 criteria for the classification of acute arthritis of primary gout. www.rheumatology.org/practice/clinical/classification/gout.asp (accessed 1 September 2014).
41. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for the therapeutic trials of non-steroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 1987;24:33-6.
42. Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Research & Therapy 2005;7 Suppl 4:S14-S22.
43. Cates CD. Visual Rx NNT Calculator, 2007. www.nntonline.net/ (accessed 1 September 2014).
44. Cohen J. Statistical Power Analysis for the Behavorial Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
45. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al.Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004;292(11):1363-4.
46. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
47. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al.Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [PUBMED: 18055266].
48. Feenstra J, Heerdink ER, Grobbee DE, Stricker BHC. Association of non-steroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Archives of Internal Medicine 2002;162:265-70.
49. Garner SE, Fidan D, Frankish RR, Judd M, Shea B, Towheed T, et al.Celecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD003831].
50. Garner SE, Fidan D, Frankish RR, Judd M, Towheed T, Tugwell P, et al.Rofecoxib for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD003685.pub2].
51. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, et al.Progress in measurement instruments for acute and chronic gout studies. Journal of Rheumatology 2009;36(10):2346-55.
52. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
55. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005521.pub2].
56. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al.British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46(8):1372-4.
57. Kearney P, Baigent C, Godwin J, Halls H, Emberson J, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis?. BMJ 2006;332:1302-8.
58. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al.2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis in acute gouty arthritis. Arthritis Care & Research 2012;64(10):1447-61.
59. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2].
60. Marks JL, Colebach AN, Buchbinder R, Edwards CJ. Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD008952.pub2].
61. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al."Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [PUBMED: 20627575].
62. Neogi T. Gout. New England Journal of Medicine 2011;364(5):443-52.
63. Pouliot M, James MJ, McColl SR, Naccache PH, Cleland LG. Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998;91:1769-76.
64. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
65. Rhody E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology 2007;46:1441-4.
66. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
67. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000396.pub3].
68. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al.Outcome domains for studies of acute and chronic gout. Journal of Rheumatology 2009;36(10):2342-5.
69. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
70. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher health-care utilization in US veterans. Annals of Rheumatic Diseases 2006;67:1310-6.
71. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. State Administration of Traditional Chinese Medicine. Criteria of Diagnosis and Therapeutic Effect of Diseases and Syndromes in Traditional Chinese Medicine. Nanjing: Nanjing University Press, 1994.
73. Wienecke T, Gotzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003789.pub2].
74. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al.EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Annals of Rheumatic Diseases 2006;65(10):1312-24.